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Abstract  
 
Objectives and methods: DETECT is a cross-sectional study of 55,518 unselected consecutive 
patients in 3188 representative primary care offices in Germany. In a random subset of 7519 
patients, an extensive standardized laboratory program was undertaken. The study 
investigated the prevalence of cardiovascular disease, known risk factors (such as diabetes, 
hypertension and dyslipidemia and their co-morbid manifestation), as well as treatment 
patterns. The present analysis of the DETECT laboratory dataset focused on the prevalence 
and treatment of dyslipidemia in primary medical care in Germany. Coronary artery disease 
(CAD), risk categories and LDL-C target achievement rates were determined in the subset of 
6815 patients according to the National Cholesterol Education Program (NCEP) ATP III 
Guidelines. Results: Of all patients, 54.3% had dyslipidemia. Only 54.4% of the NCEP-
classified dyslipidemic patients were diagnosed as ‘dyslipidemic’ by their physicians. Only 
27% of all dyslipidemic patients (and 40.7% of the recognized dyslipidemic patients) were 
treated with lipid-lowering medications, and 11.1% of all dyslipidemic patients (41.4% of the 
patients treated with lipid-lowering drugs) achieved their LDL-C treatment goals. In 
conclusion, 80.3% of patients in the sample with dyslipidemia went undiagnosed, un-treated 
or under-treated.   
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1. Introduction  
 
A recent evaluation of the Framingham and the Third National Health and nutrition 
examination survey (NHANES III) datasets revealed that more than 90% of coronary artery 
disease (CAD) events occurs in individuals with at least one of the five major CAD risk 
factors: hypertension, elevated low-density lipoproteins, low high-density lipoproteins, 
glucose intolerance and smoking [1]. Dyslipidemia thus is among the key risk factors for the 
development of cardiovascular disease.  
 
Despite minor differences in the definition of dyslipidemia and the goals of treatment between 
the major guidelines, the targets are being lowered for total cholesterol (TC) and LDL 
cholesterol (LDL-C). Recently, the European guidelines on cardiovascular disease prevention 
in clinical practice recommended a TC of below 190 mg/dl (5.0 mmol/l) and a LDL-C of 
below 115 mg/dl (3.0 mmol/l) for the general population. In dependence of the total 
cardiovascular risk and treatment success only lifestyle therapy or additional drug treatment is 
recommended. In patients with clinically established coronary artery disease (CAD), other 
cardiovascular diseases (CVD) or diabetes mellitus the recommended goals are even lower: 
TC <175 mg/dl (4.5 mmol/l) and LDL-C <100 mg/dl (2.6 mmol/l) [2]. The current National 
Cholesterol Education Program (NCEP) guidelines recommend the following LDLC levels: 
<160 mg/dl (4.1 mmol/l) in subjects with zero to one risk factors; <130 mg/dl (3.4 mmol/l) in 
subjects with two or more risk factors and a 10-year risk for hard CAD (myocardial infarction 
or CAD death) less than 20%; <100 mg/dl (2.6 mmol/l) in patients with CAD or CAD 
equivalents such as diabetes mellitus or a 10 year-risk for CAD greater than 20% [3]. In the 
UK, the LDL-C goals for patients at risk are even lower (British Hypertension Society 
guidelines) [4]. The NCEP coordination committee, encouraged by the results of recent major 
statin trials, recommended a goal for LDL-C of less than 70 mg/dl (1.8 mmol/l) in patients at 
very high risk, at least as a therapeutic option [5].We expect these therapeutic options to be 
changed into guidelines as soon as the results of two large outcome studies are available. One 
is the treating to new targets (TNT) study, which has already been published. It revealed that a 
further decrease in the LDL-C blood level from 101 mg/dl (2.6 mmol/l) to 77 mg/dl (2.0 
mmol/l), achieved with a higher statin dosage (80 mg atorvastatin versus 10 mg atorvastatin) 
significantly lowered the relative risk for the combined cardiovascular endpoint by 22% 
(absolute risk reduction 2.2%, NNT 46) [6,7]. The second study is the incremental decrease in 
end points through aggressive lipid-lowering (IDEAL) study. This study compares 
conventional-dose statin therapy (20 or 40 mg simvastatin) with a more aggressive regimen 
(80 mg atorvastatin). It thus addresses the question whether achievement of LDL-C levels 
below 70 mg/dl translates into a continuing reduction of cardiovascular risk [8].  
 
In sharp contrast to the increasing awareness and stricter cut-offs in the European and US 
American guidelines for the treatment of dyslipidemia, comparatively little is known about 
the actual situation in the setting for which most of those guidelines have been developed, 
namely the primary care sector. For example, in Germany only limited data on the prevalence 
and the distribution of risk factors are available. Most surveys have examined the prevalence 
and treatment patterns in patients at risk [9] or in a regionally clustered fashion such as 
PROCAM or MONICA or others [10–16], and many are partly out of date [8–14]. Against the 
background of the rapidly changing guidelines and treatment environment, a remarkable need 
exists for comprehensive data from large studies on the prevalence of dyslipidemia, its 
recognition and control in primary care practice. This need prompted us to initiate a nationally 
representative largescale epidemiological study (DETECT) [17,18] to assess the prevalence of 
dyslipidemia, other cardiovascular risk factors, and dyslipidemia management patterns in 
primary care.  
 
In this paper we examine: (1) the point prevalence of treated and untreated dyslipidemia in 
primary care; (2) modalities and efficacy of treatment; (3) associations between dyslipidemia 
and CVD.  
 
2. Methods  
 
2.1. Design  
 
DETECT is a large, multistage cross-sectional study of 55,518 unselected consecutive 
patients (59% women; mean age 53.9 years) in 3188 primary care offices in Germany (73% 
general medicine and 27% internal medicine) with a prospective 12-month component in a 
random subset of 7519 patients, characterized additionally by an extensive standardized 
laboratory program with focus on CV risk assessment. Patient self-assessment and physician 
assessment were obtained for each patient. Further details are available at http://www.detect-
studie.de. The rationale and design for DETECT, baseline characteristics and preliminary 
prevalence data have been published by Wittchen and Böhler et al. [17,18]. In 7376 out of the 
random subset of 7519 patients complete lipid and lipoprotein analyses were performed. Due 
to the lower and upper age boundaries of the Framingham risk score tables, Framingham risk 
scores were calculated only in the subset of 6815 patients within the age range of 20–79 years. 
A comparison of the sub-sample of 6815 patients to the total sample of 7519 patients revealed 
no relevant differences for age, sex, clinical diagnosis, BMI, smoking and alcohol 
consumption between both groups.  
 
2.2. CAD risk categories, dyslipidemia and diabetes definitions  
 
CAD risk categories and subsequent LDL-C goals were determined according to the National 
Cholesterol Education Program (NCEP) ATP III Guidelines (Table 1). Ten-year risk for hard 
CAD (MI and CAD death) was calculated according to the Framingham risk score. 
Dyslipidemia was diagnosed if LDL-C levels exceeded the target values demanded by the 
NCEP risk classes I–III, or if there was a clinical history of dyslipidemia (physician diagnosis 
or a prescription for lipid-lowering medication). The risk classes were defined as follows. 
NCEP risk class I: 0 or 1 risk factor; NCEP risk class II: 2 or more risk factors, or 10 year risk 
≤20%; NCEP risk class III: 10 year risk >20% or a diagnosis of CAD or previous stroke or 
symptomatic carotid stenosis or peripheral arterial disease (PAD). NCEP risk factors 
included: cigarette smoking, hypertension (BP ≥140/90mmHg or a prescription for 
antihypertensive medication), low HDL cholesterol (<40 mg/dL), family history of premature 
CAD (CAD in male first-degree relative <55 years; CAD in female first-degree relative <65 
years), age (men ≥45 years; women ≥55 years) [3]. Due to a recent publication by Hense et al. 
[19], which reported an overprediction of the CV risk in Germany by using the Framingham 
score, we additionally performed the PROCAM risk calculation for dyslipidemia prevalence 
estimations as well.  
 
Diabetes was defined according to the guidelines of the American Diabetes Association 
(fasting plasma glucose >126 mg/dl, no caloric intake for at least 8 h) or clinical history 
(physician diagnosis or prescription for an antidiabetic medication).  
 
2.3. Blood pressure measurements  
 
Blood pressure measurements were performed according to the guidelines of the German 
Hypertension Society.  
 
2.4. Lipids and lipoproteins  
 
Fasting blood samples were collected and shipped by courier within 24 h to the central 
laboratory at the Medical University of Graz (Austria). Clinical chemical parameters as well 
as cholesterol, triglycerides and lipoprotein (a) [Lp(a)] were determined on a Roche Modular 
automatic analyser. Lipoproteins (HDL, LDL and VLDL) were determined 
electrophoretically on the HELENA SAS-3/SAS-4 system. Haemoglobin (Hb) A1c was 
determined chromatographically on an ADAMS HA 8160 analysing system. For all 
parameters, reagents and secondary standards were used as recommended by the 
manufacturers.  
 
2.5. Statistical analyses  
 
Prevalence estimates were based on the assessment of the laboratory subset of unselected 
consecutive primary care attendees in the participating centers on the study day and are thus 
point prevalence estimates. The data were weighted to adjust for non-response and differences 
in the laboratory sampling process between the laboratory sample and the main study sample. 
Using cross tables, frequency distributions and descriptive statistics, we compared the 
distributions of variables among all categories. All statistical analyses were conducted with 
the software package STATA8 [20].  
 
3. Results  
 
3.1. Patient population  
 
A total of 4086 patients (54.3%) out of the 6815 patients with complete Framingham risk 
classification were identified as dyslipidemic by the criteria of the NCEP ATPIII guidelines. 
Only 1170 patients received lipid-lowering medication (27% of all patients with 
dyslipidemia).  
 
Among those with dyslipidemia, patients treated with lipid-lowering (LL) drugs were older, 
smoked less, had a lower total cholesterol, a lower LDL-cholesterol and slightly higher levels 
of triglycerides than those not receiving LL drugs. In the latter, more patients had HbA1c 
serum levels over 6.5% and more patients with fasting plasma glucose levels over 126 mg/dl. 
The rates of overweight and obese patients, the amount of alcohol consumed, serum creatinine 
levels and blood pressure and heart rate were comparable between groups. Based on physician 
diagnosis, the medically treated group had significantly higher rates of patients with metabolic 
and cardiovascular diseases such as diabetes, hypertension, myocardial infarction, stroke and 
atherosclerotic diseases (CAD or carotid stenosis or PAD). Interestingly, only 45.4% of the 
dyslipidemic patients without lipid-lowering treatment were classified by their physicians as 
being dyslipidemic compared to 82.0% in the group treated with lipid-lowering compounds.  
 
Table 2 summarizes the demographic characteristics and medical history of the total sample 
(n = 6815), the group of patients with NCEP dyslipidemia, and the groups of medically 
untreated and treated patients.  
 
3.2. NCEP risk classification  
 
Of the patients with NCEP dyslipidemia, 20.8% were classified as NCEP risk class I, and 
27% as NCEP risk class II with no major difference in gender, 52.2% were classified as 
NCEP risk class III with a higher portion of men. The age distribution of dyslipidemia shows 
a continuous increase with age; the majority of patients with NCEP dyslipidemia are over 50 
years old. Only 0.5% of the dyslipidemic patients were younger than 30 years, mostly 
classified as NCEP risk class I or II.  
 
In the group between 20 and 29 years of age, 15.4% of patients were within NCEP risk class 
III. The proportion of patients within NCEP risk class III continuously increased with age and 
represented the majority of patients in the age group between 50 and 59 years. In the age 
group between 70 and 79 years, most patients were classified as NCEP risk class III (86.2%). 
Men were more frequently classified as NCEP risk class III compared to women and achieved 
this NCEP risk class at an earlier age. Table 3 and Fig. 1 lists the age and sex dependent rates 
by ATPIII NCEP risk classes I–III.  
 
3.3. Assignment of dyslipidemia diagnoses  
 
Only 2387 (54.4%) of the of 4086 NCEP dyslipidemic patients were diagnosed as 
‘dyslipidemic’ by their physicians, with no major gender differences. The frequency of being 
diagnosed as dyslipidemic increased with age, ranging from 22.8% in patients in the age 
group 20–29 years to nearly 60% in the age group 60–69 years (Table 4a). The rate of 
diagnosed dyslipidemia was higher in NCEP risk classes I and III compared to NCEP risk 
class II (61.5% and 57.4%, respectively versus 43%).  
 
3.4. Treatment rates  
 
A total of 1170 (27%) (Table 4a) of the NCEP dyslipidemic patients and 976 (40.7%) (Table 
4b) of the recognized dyslipidemic patients were treated with lipid-lowering medication. The 
majority of the recognized patients received additional lifestyle interventions (70%) with a 
higher rate in men than women, which significantly increased with age (Table 4b). Especially 
inNCEPrisk class I, significantly more men than women received lipid-lowering treatment 
(26% versus 16.3% and 35.9% versus 20.2% in the recognized patients) mostly in the age 
group between 30 and 59 years. In NCEP risk classes II and III, no major gender or age-
related differences were observed, except for an approximately 10% higher rate of lipid-
lowering treatment in men compared to women in the NCEP risk class III, across the age 
groups from 40 to 69 years.  
 
3.5. LDL-C goal achievement  
 
Only 41.4% of patients treated with lipid-lowering drugs were at their target level for LDL-C 
(11.1% of all dyslipidemic patients, respectively). Men achieved their goals more frequently 
than women (Table 4a). In NCEP risk class I, significantly more patients achieved their target 
level than did those in NCEP risk classes II and III (13.2% versus 8.6% and 11.7%, 
respectively).  
 
A total of 10.8% of all patients achieved their NCEP LDL-C goal without any lipid-lowering 
treatment. Most of these patients were in the age group between 20 and 49 years, and women 
achieved their goals without treatment more frequently than men (Table 4a). This effect can 
be found throughout all NCEP risk classes. The proportion of these patients was higher within 
NCEP risk class I (31.6%) compared to NCEP risk classes II and III (8.7% and 3.6%, 
respectively). Table 4a and Fig. 2 summarize the categories and age and sex-dependent rates 
of dyslipidemia diagnosis, lipid-lowering treatment and goal achievement for LDL-C, Table 
4b summarizes the rates and types of lipid-lowering intervention for patients with clinically 
diagnosed dyslipidemia.  
 
3.6. Under-recognition and under-treatment of dyslipidemia  
 
Of all patients with NCEP dyslipidemia, 45.6% have not been identified by their treating 
physician as dyslipidemic; 21.4% have been recognized but not treated with lipid-lowering 
drugs; 13.2% have been recognized and treated but have not achieved their treatment goals. 
Dyslipidemia in the elderly was unrecognized less frequently; however, these patients were 
more frequently under-treated and showed significantly lower goal achievement rates 
compared to younger patients. The recognition rates were significantly better in patients with 
MI and PAD and only slightly better in patients with stroke, hypertension and diabetes 
mellitus. The treatment rates were better in patients with MI and stroke (only 13.6% and 
20.9% of the patients were recognized but not treated with lipid-lowering drugs compared to 
21.4% overall). Goal achievement was worse in patients with CV diseases or in patients at 
high risk. The rates of treated patients not at goal were worse in patients with MI, PAD, 
stroke, hypertension and diabetes mellitus. Table 5 shows age-dependent rates for under-
recognition, under-treatment and under-achievement of goals for dyslipidemia in all patients 
with NCEP dyslipidemia and subgroups with CV diseases and distinct CV risk factors.   
 
3.7. Unmet needs  
 
Dyslipidemia without diagnosis from the treating physician or with inadequate or no lipid-
lowering medical treatment (‘unmet needs’) were present in 80.3% of all patients with NCEP 
dyslipidemia, with no major differences across the age clusters. The majority of unmet needs 
result from patients with unrecognized disease (45.6% of the NCEP dyslipidemia patients) 
(Tables 6a and 6b).  
 
3.8. Drug treatment  
 
In the group of patients with treated dyslipidemia, the most frequently used lipid-lowering 
(LL) drug classes were statins (87%), followed by fibrates (10.2%), ezetimibe (4.4%), omega-
3-FAs (4.1%), nicotinic acid derivates (1.6%) and bile acid sequestrants (0.4%). The rates for 
fibrates were lower in NCEP risk class I (6.1%) than in classes II and III (12.6% and 10.5%, 
respectively). The rates for the use of statins were higher in the NCEP risk class III (88.9%) 
than in I and II (83.8% and 81.9%, respectively) (Fig. 3).  
 
A total of 92.9% of the patients treated with lipid-lowering drugs received one, two (6.5%) or 
three (0.5%) different lipid-lowering compounds. Double combinations were mostly statin–
ezetimibe combinations (3.1%) and statin–fibrate combinations (1.5%). Triple combinations 
were very rare and mostly statin-ezetimibe–omega-3-FA combinations (0.2%) (Table 7). 
Exactly 14.1% of all recognized patients received only lipid-lowering drugs; 50% received no 
lipid-lowering drugs but did receive lifestyle interventions; 35.9% were treated with both 
approaches. The combined approach was used significantly more frequently in NCEP risk 
class III compared to classes I and II (Fig. 4).  
 
4. Discussion  
 
The present study had four key findings. First, in a group of unselected patients attending a 
primary care practice, approximately 50% could be classified as having a NCEP dyslipidemia. 
More than half of these patients were classified as being in the NCEP risk class III, and more 
than 60% were aged 60 years or older, with a continuous increase of dyslipidemia with age. 
Second, the prevalence of dyslipidemia merely based on physician diagnosis should be 
considered with caution. Only half of the NCEP-classified dyslipidemic patients in our sample 
were diagnosed as ‘dyslipidemic’ by their physicians. Third, the treatment and goal 
achievement rates for dyslipidemia were low. Only around 40% of recognized patients and 
only a quarter of all NCEP dyslipidemic patients were treated with lipid-lowering 
medications, with a significantly higher treatment rate in men compared to women. And 
fourth, only around 40% of the patients treated with lipid-lowering drugs achieved their 
NCEP treatment goals for LDL-C (10% of all dyslipidemic patients). In general, dyslipidemia 
in the elderly is more frequently diagnosed, but it is less frequently medically treated and at 
goal in this group. Compared to the overall group, the recognition and treatment rates in 
patients with CV diseases and diabetes were better, although goal attainment was worse. 
Interestingly, a remarkable number of the recognized dyslipidemic patients (14%) were 
treated solely with LL compounds without additional lifestyle intervention, which should be 
the basic therapy for these patients. The treating physicians however did not provide reasons 
for this decision and the corresponding patient data did not contain any other measure of 
lifestyle intervention indicating that this has been done by intention (missing knowledge or 
ignorance of guidelines or simply patients non-compliance).  
 
Unmet needs (no recognition of dyslipidemia, no or insufficient medical treatment) have been 
identified for approximately 80% of the dyslipidemic patients, with under-recognition as the 
major cause (approximately 45%).  
 
These figures are alarming. If these point prevalence results are extrapolated to the entire 
patient population attending the over 60,000 primary care settings in Germany on an average 
day, around 1.8 million patients with dyslipidemia are seen by primary care physicians, but 
only 500,000 are treated with lipid-lowering drugs and only around 50,000 are at goal.  
 
When these data from the primary care sector are compared to findings from population based 
cohort studies such as MONICA [11], PROCAM [10], or GRIPS [22], obviously more 
patients are suffering from dyslipidemia, even if different definitions for dyslipidemia have 
been used, such as the TC/HDL-C ratio in the MONICA cohort from 1984 to 1992. Our data 
however, in contrast to these investigations are representative for the entire primary care 
sector, and thus more relevant and applicable to daily life situations in clinical practice.  
 
Moreover, the dyslipidemia prevalence assumptions used in our evaluation could even be 
worse. If we used the lower LDL-C goals of <70 mg/dl for patients at very high 
cardiovascular risk recommended by the British Hypertension Society (BHS guidelines) in the 
UK or published as a therapeutic option from the Coordinating Committee of the National 
Cholesterol Education Program (NCEP ATP III) in the USA, the numbers would be even 
higher [4,5]. There is an unequivocal agreement about the LDL-C goal of below 100 mg/dl 
for patients with CAD in the major guidelines [2,3,23]. They differ regarding 
recommendations for the prevention of cardiovascular events in asymptomatic high risk 
patients, notably in the strategy to be used for the risk assessment. For patients with lower 
NCEP risk classifications, for example, the European guidelines recommend an optimal LDL-
C level of below 115 mg/dl, which would increase the estimate of dyslipidemic patients 
tremendously [2].  
 
On the other hand, an overprediction of the Framingham risk function of approximately 50% 
could be shown in an evaluation of the German MONICA and PROCAM cohorts, which 
would mean a lower effective cardiovascular risk with accordingly higher LDL-C goals and 
thus lower prevalence rates for dyslipidemia in these patients. These results suggest the 
PROCAM risk calculator may be more appropriate for a German population [19]. Thus we 
felt it appropriate to calculate patient risk with the PROCAM risk calculator as well [19,21]. 
Using the PROCAM calculator for our population, we found slightly higher prevalence rates 
of dyslipidemia (57% PROCAM versus 54.3% Framingham), an identical physician diagnosis 
rate (54.4%), and similar treatment and goal achievement rates for dyslipidemia. ‘Unmet 
needs’ could be found in even more patients (82.3%) compared to the Framingham-based 
assessment (80.3%). Thus our data did not reveal any meaningful difference between the 
PROCAM and the Framingham risk calculations, clearly in disagreement with the findings by 
Hense et al. [19].  
 
In our study, we used the Framingham-based NCEP guidelines for the definition and 
classification of dyslipidemia. The variety of national and international guidelines and 
definitions for those risk factors, however, requires additional comparative evaluations of data 
sets, especially in the primary care sector, to see which of the different guidelines and 
definitions best reflects the situation in Germany [23].  
 
Of course the recommendation for lipid-lowering therapy as a minimum requirement for each 
patient with dyslipidemia would have tremendous cost implications, and health care systems 
have to carefully consider feasible ways to translate treatment recommendations into practical 
and cost-effective guidelines. This highlights the urgent need to further identify populations at 
risk which benefit in particular of lipid-lowering treatments, as the ASCOT study just recently 
did.  
 
In ASCOT, a population at risk (N= 10,305) defined as patients with hypertension and 
additional risk factors (e.g. mean LDL-C level 130 mg/dl), underwent lipid-lowering 
treatment with 10 mg of the HMG-CoA inhibitor atorvastatin and achieved a highly 
significant 36% reduction in combined cardiovascular risk (absolute risk reduction 1.1%, 
NNT 91) [24]. More realistic outcome trials with populations similar to the real-life primary 
care population such as used in ASCOT and performed in Germany are the next logical steps 
in translating the results from drug studies in highly controlled settings into daily clinical 
practice.  
 
In summary, our results indicate that a significant proportion of patients in primary care are 
dyslipidemic and thus at increased risk for cardiovascular events. However, lipid-lowering 
therapy in this group of patients seems to be sub-optimal, clearly indicating the need of 
concerted efforts to improve treatment rates for elevated blood lipids.  
 
Given the high prevalence of dyslipidemia in primary care, low recognition rates, low medical 
treatment and goal achievement rates, much could be achieved if recognition and subsequent 
treatment rates would increase and goal attainment, especially in secondary prevention, would 
improve. Plenty of room remains for improvement in prevention and treatment of 
cardiovascular disease in the primary care sector, as a pivotal part in the health care system.    
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